Deutsche Bank AG Reiterates “Buy” Rating for Eli Lilly and Co. (LLY)
Eli Lilly and Co. (NYSE:LLY)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank AG in a note issued to investors on Tuesday.
Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. raised Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $92.00 to $95.00 in a report on Thursday, September 8th. Leerink Swann reaffirmed an “outperform” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Saturday, August 13th. Jefferies Group reaffirmed a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Wednesday, September 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, SunTrust Banks Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Buy” and a consensus price target of $96.85.
Eli Lilly and (NYSE:LLY) traded up 0.86% on Tuesday, hitting $80.57. The company had a trading volume of 1,947,600 shares. The company has a market capitalization of $85.22 billion, a P/E ratio of 34.73 and a beta of 0.20. The stock’s 50-day moving average price is $79.51 and its 200 day moving average price is $76.76. Eli Lilly and has a one year low of $67.88 and a one year high of $88.48.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/deutsche-bank-ag-reiterates-buy-rating-for-eli-lilly-and-co-lly-2.html
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.86. The business had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. Eli Lilly and’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS. On average, analysts expect that Eli Lilly and will post $3.59 EPS for the current fiscal year.
In other news, insider Donald A. Zakrowski sold 1,213 shares of the company’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the transaction, the insider now directly owns 1,300 shares of the company’s stock, valued at $108,108. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jackson P. Tai bought 2,560 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The stock was acquired at an average cost of $80.42 per share, with a total value of $205,875.20. Following the completion of the acquisition, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The disclosure for this purchase can be found here. 0.20% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Iowa State Bank purchased a new position in Eli Lilly and during the second quarter valued at approximately $104,000. PineBridge Investments L.P. increased its position in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the last quarter. Cribstone Capital Management LLC purchased a new position in Eli Lilly and during the second quarter valued at approximately $117,000. Coconut Grove Bank increased its position in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock valued at $122,000 after buying an additional 50 shares during the last quarter. Finally, Physicians Financial Services Inc. increased its position in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares during the last quarter. 74.96% of the stock is owned by institutional investors.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.